featured
Tissue-Specific Thresholds of Mutation Burden Associated With Anti–PD-1/Anti–PD-L1 Therapy Benefit and Prognosis in Microsatellite-Stable Cancers
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers
Nat Cancer 2024 Mar 25;[EPub Ahead of Print], M Muquith, M Espinoza, A Elliott, J Xiu, A Seeber, W El-Deiry, ES Antonarakis, SL Graff, MJ Hall, H Borghaei, DSB Hoon, SV Liu, PC Ma, RR McKay, T Wise-Draper, J Marshall, GW Sledge, D Spetzler, H Zhu, D HsiehchenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.